An in-vitro evaluation of three types of drug-eluting microspheres loaded with irinotecan.

abstract：:Since the early 1990s, mitoxantrone has been used as a chemotherapeutic agent for adjuvant intravesical treatment following transurethral resection of superficial transitional cell carcinomas of the bladder. Although its efficacy as adjuvant intravesical therapy remains questionable and its use has not gained wide acc...

journal_title：Anti-cancer drugs

authors： Giannakopoulos S,Pantazis T,Kalaitzis C,Antoniou D,Patris E,Touloupidis S

更新日期：2008-03-01 00:00:00

abstract：:Extrachromosomal DNA is the predominant form of gene amplification in human tumors. Hydroxyurea (HU) concentrations of 100-150 microM have been promising in vitro for extrachromosomal DNA elimination. The study objective was to determine the HU dose-concentration relationship in nude mice with HU doses from 0 to 200 m...

journal_title：Anti-cancer drugs

authors： Van den Berg CL,McGill JR,Kuhn JG,Walsh JT,De La Cruz PS,Davidson KK,Wahl GM,Von Hoff DD

更新日期：1994-10-01 00:00:00

abstract：:In this study, we investigated the putative cytotoxic effect elicited by the garlic-derived compound S-allylcysteine (SAC) in two human cancer cell lines (HCC827 and NCI-H1975) in order to develop an experimental approach to the therapeutic potential of this molecule for lung cancer. Cells were incubated for 24, 48 an...

journal_title：Anti-cancer drugs

authors： Orozco-Morales M,Hernández-Pedro NY,Barrios-Bernal P,Arrieta O,Ruiz-Godoy LM,Aschner M,Santamaría A,Colín-González AL

更新日期：2021-02-01 00:00:00

abstract：:A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were...

journal_title：Anti-cancer drugs

authors： Gedlicka C,Schüll B,Formanek M,Kornfehl J,Burian M,Knerer B,Selzer E,Scheithauer W,Kornek GV

更新日期：2002-06-01 00:00:00

abstract：:This study aims to investigate the significance and mechanism of artesunate involved in suppressing the proliferation of gastric cancer in vitro and in vivo. In the in-vitro experiments, artesunate inhibited the growth of gastric cancer cell lines (SGC-7901, BGC-823, and AGS) with concentration-dependent activity, wit...

journal_title：Anti-cancer drugs

authors： Zhou X,Sun WJ,Wang WM,Chen K,Zheng JH,Lu MD,Li PH,Zheng ZQ

更新日期：2013-10-01 00:00:00

abstract：:The results of several preclinical and clinical studies were reported by oncology professionals at the 43rd American Society of Clinical Oncology (ASCO) meeting, the largest international forum in which the latest achievements in cancer research are annually presented. The central theme this year was 'Translating Rese...

journal_title：Anti-cancer drugs

authors： Puglisi F,Aprile G,Fasola G

更新日期：2008-02-01 00:00:00

abstract：:The use of viability assays to assess the effect of antineoplastic agents on cell lines and tumor cells is an important investigative tool and may have clinical relevance. Such assays require very small quantities of drugs and it is the practice of many laboratories to freeze aliquots of drugs for use in these assays ...

journal_title：Anti-cancer drugs

authors： Hunter EM,Sutherland LA,Cree IA,Subedi AM,Hartmann D,Linder D,Andreotti PE

更新日期：1994-04-01 00:00:00

abstract：:It is well known that the anti-cancer drug cisplatin has an ototoxic property; however, the details are not yet evident. In this study, the expression of inducible nitric oxide synthase (INOS/NOS II) in the vestibule of guinea pigs after i.p. injections of cisplatin was examined immunohistochemically. Three days after...

journal_title：Anti-cancer drugs

authors： Watanabe K,Hess A,Bloch W,Michel O

更新日期：2000-01-01 00:00:00

abstract：:This multi-center trial was carried out to assess the therapeutic potential of recombinant tumor necrosis factor (rTNF) as the first form of systemic therapy for advanced carcinomas of gastric and pancreatic origin. To be eligible patients were required to have no overt sign of coagulopathy and hepatic function studie...

journal_title：Anti-cancer drugs

authors： Muggia FM,Brown TD,Goodman PJ,Macdonald JS,Hersh EM,Fleming TR,Leichman L

更新日期：1992-06-01 00:00:00

abstract：:Two young adults that presented with intra-abdominal desmoplastic small cell tumors (DSCT) without any evidence of a primary site are described. Both cases share the clinical characteristic features of this rare tumor which include predominant intra-abdominal location as initial presentation, nesting pattern of growth...

journal_title：Anti-cancer drugs

authors： Liau CT,Yang TS,Wang CH,Hsueh S

更新日期：1996-02-01 00:00:00

abstract：:Metastases of prostate cancer originating from the parotid gland are rare. However, this presentation raises the question of the management of visceral metastasis in castration-resistant prostate cancer. We report the case of an 87-year-old man who presented with a right painless parotid mass in the context of castrat...

journal_title：Anti-cancer drugs

authors： Hélissey C,Rouanne M,Arnaud FX,Le Moulec S

更新日期：2015-03-01 00:00:00

abstract：:CHS 828, a pyridyl cyanoguanidine, is a new drug candidate now in phase I/II trials, that has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. In this study the fluorometric microculture cytotoxicity assay was used for evaluation of CHS 828 in primary...

journal_title：Anti-cancer drugs

authors： Frost BM,Lönnerholm G,Nygren P,Larsson R,Lindhagen E

更新日期：2002-08-01 00:00:00

abstract：:In a previous study, we showed that a combination of an oral fluoropyrimidine anticancer agent (S-1) and gemcitabine (GEM) had synergistic effects on cell growth and cell cycle arrest in the pancreatic cancer cell line MIA PaCa-2. Therefore, we conducted further mechanistic studies using the pancreatic cancer cell lin...

journal_title：Anti-cancer drugs

authors： Morimoto Y,Takeuchi O,Takizawa A,Yoneyama H,Asanuma F,Suzuki Y,Atsuda K,Yamada Y

更新日期：2012-06-01 00:00:00

abstract：:Phase II trials of the novel biologic combination of 13-cis-retinoic acid plus interferon (IFN)-alpha have achieved major activity in advanced squamous cell carcinomas of the skin and cervix, but not of the lung or head and neck. Very limited study of this combination has occurred in cancers other than those of squamo...

journal_title：Anti-cancer drugs

authors： Kudelka AP,Freedman RS,Edwards CL,Lippman SM,Tornos CS,Krakoff IH,Kavanagh JJ

更新日期：1993-06-01 00:00:00

abstract：:The aim of this study was to identify the most potent quinoline-based anti-infectives for the treatment of multiple myeloma (MM) and to understand the molecular mechanisms. A small-scale screen against a panel of marketed quinoline-based drugs was performed in MM cell lines. Cell apoptosis was examined by flow cytomet...

journal_title：Anti-cancer drugs

authors： Mao H,Du Y,Zhang Z,Cao B,Zhao J,Zhou H,Mao X

更新日期：2017-04-01 00:00:00

abstract：:The beta-carboline alkaloids are naturally existing plant substances. It is known that these alkaloids have a wide spectrum of neuropharmacological, psychopharmacological, and antitumor effects. Therefore, they have been traditionally used in oriental medicine for the treatment of various diseases including cancers an...

journal_title：Anti-cancer drugs

authors： Abe A,Yamada H

更新日期：2009-06-01 00:00:00

abstract：:The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

journal_title：Anti-cancer drugs

authors： Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

更新日期：2006-10-01 00:00:00

abstract：:The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7 resistant to adria...

journal_title：Anti-cancer drugs

authors： Chen Q,Meng YQ,Xu XF,Gu J

更新日期：2017-09-01 00:00:00

abstract：:Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old wom...

journal_title：Anti-cancer drugs

authors： Hirashima Y,Kobayashi H,Nishiguchi T,Miura K,Kanayama N

更新日期：2001-08-01 00:00:00

abstract：:Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

journal_title：Anti-cancer drugs

authors： Ma W,Liu X,Du W

更新日期：2019-02-01 00:00:00

abstract：:The goal of this study was to identify clinical characteristics and concurrent medications associated with an increased or decreased incidence of cisplatin-induced nephrotoxicity. The medical records for 62 subjects with head and neck cancer who received cisplatin 100 mg/m2 (day 1) plus fluorouracil 1000 mg/m2 (days 1...

journal_title：Anti-cancer drugs

authors： Shord SS,Thompson DM,Krempl GA,Hanigan MH

更新日期：2006-02-01 00:00:00

abstract：:We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib. The serum levels of sP-selectin and TxB2 increased significantly in all patients who received gefitinib...

journal_title：Anti-cancer drugs

authors： Kanazawa S,Yamaguchi K,Kinoshita Y,Muramatsu M,Komiyama Y,Nomura S

更新日期：2006-04-01 00:00:00

abstract：:Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

journal_title：Anti-cancer drugs

authors： Mastronardi L,Puzzilli F,Ruggeri A

更新日期：1998-08-01 00:00:00

abstract：:Prostaglandin E2 (PGE2) has been shown to play an important role in tumor development and progression. PGE2 mediates its biological activity by binding any one of four prostanoid receptors (EP1 through EP4). The present study was designed to determine the role of the EP2 receptor during the proliferation and apoptosis...

journal_title：Anti-cancer drugs

authors： Hu S,Sun W,Wei W,Wang D,Jin J,Wu J,Chen J,Wu H,Wang Q

更新日期：2013-02-01 00:00:00

abstract：:We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

journal_title：Anti-cancer drugs

authors： Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

更新日期：1999-07-01 00:00:00

abstract：:Vinblastine at doses ranging from 0.2 to 6 mg/kg body weight was administered i.p. to mice in the absence or presence of the drugs PSC 833, cyclosporin A, mefloquine, quinidine and dipyridamole, all compounds that modulate the multidrug resistance pump and thus increase the accumulation of this cytotoxin in drug-resis...

journal_title：Anti-cancer drugs

authors： Lyubimov E,Lan LB,Pashinsky I,Stein WD

更新日期：1996-01-01 00:00:00

abstract：:Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

journal_title：Anti-cancer drugs

authors： Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

更新日期：2016-06-01 00:00:00

abstract：:Glucocorticosteroids (GC) play an important role in the treatment of neuro-oncologic patients. GC are used for the management of malignant brain tumors, either primary of secondary, neoplastic epidural spinal cord compression (NESC), as adjuvant chemotherapy of some central nervous system tumors and perioperatively in...

journal_title：Anti-cancer drugs

authors： Koehler PJ

更新日期：1995-02-01 00:00:00

abstract：:Tafluposide (F 11782), a novel epipodophylloid with a unique mechanism of interaction with both topoisomerase I and II, has shown outstanding antitumor activity in vivo against a panel of experimental human tumor xenografts. The aim of this study was to evaluate its cytotoxicity against fresh tumor cells taken from pa...

journal_title：Anti-cancer drugs

authors： Sargent JM,Elgie AW,Williamson CJ,Hill BT

更新日期：2003-07-01 00:00:00

abstract：:Anemia is a common side effect of cisplatin, especially after repeated infusions. The primary mechanisms is a myelosuppression caused by cisplatin's interference with iron metabolism, resulting in a lower count of red cell precursors. Some authors report a hemolytic anemia similar to penicillin-induced anemia, in whic...

journal_title：Anti-cancer drugs

authors： Maloisel F,Kurtz JE,Andres E,Gorodetsky C,Dufour P,Oberling F

更新日期：1995-04-01 00:00:00